Accueil   Diary - News   All news PDC*line Pharma receives ATMP classification

PDC*line Pharma receives ATMP classification

PDC*line Pharma receives Advanced-Therapy Medicinal Product (ATMP)
classification from the European Medicines Agency (EMA) for its new class of
therapeutic cancer vaccines (PDC*vac)


PDC*line Pharma, a clinical-stage biotech company, announces that PDC*vac, its new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic Cells (PDC*line), was granted Advanced-Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA), in consultation with the European Commission. The EMA / CAT considers that PDC*vac fulfills the definition of an Advanced-Therapy Medicinal Product (ATMP), within the Somatic-Cell Therapy Medicinal Product category.


Read the press release